In adults, FGFR4 overexpression and amplification (identified in 13% of pediatric tumors and 30% of adults) was associated with worse outcomes.[82] A phase II trial investigating the efficacy of dovitinib, a tyrosine kinase inhibitor with nonselective activity against the FGFR, included 17 patients with unresectable ACC.[83] One partial response was documented but 23% of patients achieved stable disease lasting >6 months. This evidence concerns the gene FGFR4 and adrenal cortex carcinoma.